

SUPPLEMENTARY MATERIAL

No Statistically Apparent Difference in Antifungal Effectiveness Observed Among Trimethoprim/Sulfamethoxazole Plus Clindamycin or Caspofungin, and Trimethoprim/Sulfamethoxazole Monotherapy in HIV-Infected Patients with Moderate to Severe Pneumocystis Pneumonia: Results of an Observational Multicenter Cohort Study

Yinqiu Huang^{1,2#}, Xiaoqing He^{1#}, Hui Chen³, Vijay Harypursat¹, Yanqiu Lu¹, Jing Yuan¹, Jingmin Nie¹, Min Liu¹, Jianhua Yu⁴, Yulin Zhang⁵, Zhongsheng Jiang⁶, Yingmei Qin⁷, Lijun Xu⁸, Guoqiang Zhou⁹, Defa Zhang¹⁰, Xiaohong Chen¹¹, Baisong Zheng¹², Yaokai Chen^{1, 2*}

¹*Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China*

²*National Key Laboratory for Infectious Diseases Prevention and Treatment with Traditional Chinese Medicine, Chongqing Public Health Medical Center, Chongqing, China*

³*School of Biomedical Engineering, Capital Medical University, Beijing, China*

⁴*Department of Infectious Diseases, Xixi Hospital of Hangzhou, Zhejiang, China*

⁵*Division of Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China,*

⁶*Division of Infectious Diseases, Liuzhou People's Hospital, Liuzhou, Guangxi, China*

⁷*Division of Infectious Diseases, the Fourth People's Hospital of Nanning, Guangxi, China*

⁸ *Division of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang, China*

⁹*Division of Infectious Diseases, the First Hospital of Changsha, Hunan, China*

¹⁰ *Department of Infectious Diseases, Tianjin Second People's Hospital, Nankai University,*

Tianjin, China

¹¹*Department of Infectious Diseases, the Fourth Affiliated Hospital of Harbin Medical*

University, Harbin, China

¹²*Institute of Virology and AIDS Research, the First Hospital of Jilin University, Changchun*

130021, China

#These authors contributed equally to this work

**Correspondence to:*

Dr. Yao-Kai Chen, Division of Infectious Diseases, Chongqing Public Health Medical Center, 109

Baoyu Road, Geleshan Town, Shapingba District, Chongqing 400036, China.

Email: yaokaichen@hotmail.com.

Table 1.

No.	Institution	Name of the ethics committee	Ethics Approval No.
1	Chongqing Public Health Medical Center	Ethics Committee of the Chongqing Public Health Medical Center	2019-003-02-KY
2	Beijing Youan Hospital, Capital Medical University	The Institutional Ethics Committee of Beijing Youan Hospital, Capital Medical University	LL-2019-053-K
3	The Fourth Affiliated Hospital of Harbin Medical University,	Ethics Committee of the Fourth Affiliated Hospital of Harbin Medical University	2019-WZYSLLSC-01
4	Tianjin Second People's Hospital, Nankai University,	Medical Ethics Committee of Tianjin Second People's Hospital	2019-07
5	The First Hospital of Changsha	Ethics committee of the First Hospital of Changsha	KX-2019028
6	Guangzhou Eighth People's Hospital	Ethics committee of Guangzhou Eighth People's Hospital	201908121
7	Liuzhou People's Hospital	Ethics committee of Liuzhou People's Hospital	2019-02-01
8	The Third People's Hospital of Guilin	Ethics committee of the Third People's Hospital of Guilin	2019-003-02-KY
9	Shenzhen Third People's Hospital	Ethics committee of Shenzhen Third People's Hospital	2019-005
10	Chengdu Public Health Clinical Medical Center	Ethics committee of Chengdu Public Health Clinical Medical Center	YJ-K2019-008-01
11	Kunming Third People's Hospital	Ethics committee of Kunming Third People's Hospital	2020052602
12	Yunnan Provincial Infectious Disease Hospital	Ethics committee of Yunnan Provincial Infectious Disease Hospital	201905
13	The Fourth People's Hospital of Nanning	Ethics committee of the Fourth People's Hospital of Nanning	2019-005
14	Longtan Hospital of Guangxi Zhuang Autonomous Region	Ethics committee of Longtan Hospital of Guangxi Zhuang Autonomous Region	20191005
15	The First Affiliated Hospital, College of Medicine, Zhejiang University	Ethics Committee of The Second Affiliated Hospital, School of Medicine, Zhejiang University.	No. 2019-034
16	Xixi Hospital of Hangzhou	Ethics Committee of Xixi Hospital of Hangzhou	2019-007

Table 2.

	Enrolled Group (n=320)	Excluded Group (n=36)	p-value
Age, median years (IQR)	48.0 (37.0, 56.0)	51.0 (38.2, 60.8)	0.440
Male gender, n (%)	70 (21.88%)	6 (16.67%)	0.517
BMI, median kg/m ² (IQR)	20.3 (18.5, 22.5)	21.3 (19.4, 23.2)	0.169
Route of infection, n (%)			0.001
MSM	48 (15.00%)	15 (41.67%)	
Heterosexual	180 (56.25%)	10 (27.78%)	
Other	5 (1.56%)	0 (0.00%)	
Unknown	87 (27.19%)	11 (30.55%)	
ART, n (%)	14 (4.38%)	5 (13.89%)	0.038
Smoking, n (%)	114 (35.63%)	6 (16.67%)	0.028
Alcohol use, n (%)	67 (20.94%)	3 (8.33%)	0.081
Other medical conditions, n (%)			
Diabetes mellitus	10 (3.13%)	5 (13.89%)	0.008
Hypertension	5 (1.56%)	0 (0.00%)	1.000
Tuberculosis	34 (10.63%)	2 (5.56%)	0.536
HIV RNA, median log ₁₀ copies/mL (IQR)	5.6 (5.1, 5.9)	5.2 (4.6, 5.5)	0.022
CD4 ⁺ T-cell counts, cells/mm ³ , n (%)	307	28	0.263
<50	239 (77.85%)	20 (71.43%)	
50-100	43 (14.01%)	3 (10.71%)	
101-200	19 (6.19%)	4 (14.29%)	
>200	6 (1.95%)	1 (3.57%)	
HGB, mean × 10 ⁹ /L ± SD	117.19 ± 19.61	120.97 ± 19.45	0.285
PLT, median × 10 ⁹ /L (IQR)	237.0 (170.0, 300.0)	218.0 (172.3, 292.8)	0.544
G test, IQR	203.9 (72.2, 486.7)	127.9 (30.8, 325.0)	0.190

Scr, median $\mu\text{mol/L}$ (IQR)	63.8 (52.5, 74.6)	67.2 (57.8, 83.3)	0.148
AST, median U/L (IQR)	37.0 (27.0, 52.0)	29.5 (23.5, 46.1)	0.053
ALT, median U/L (IQR)	22.0 (13.3, 38.0)	20.8 (15.3, 38.5)	0.801
LDH, median U/L (IQR)	430.5 (327.0, 540.3)	465.0 (328.3, 592.0)	0.615
PaO ₂ , median kPa (IQR)	57.0 (50.0, 63.0)	57.0 (49.7, 66.0)	0.617
